The biology and the genetics of Hürthle cell tumors of the thyroid

Endocrine-Related Cancer

Volumn 19, Issue 4, 2012, Pages

  Máximo, Valdemar ^a,b   Lima, Jorge ^a,b   Prazeres, Hugo ^a,c   Soares, Paula ^a,b   Sobrinho Simões, Manuel ^a,b,d  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c Instituto Portugues de Oncologia Francisco Gentil Centro Regional de Oncologia de Coimbra SA   (Portugal)

^d HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

MITOCHONDRIAL DNA; MICRORNA;

CANCER DIAGNOSIS; CANCER GENETICS; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; CELL STRUCTURE; CELL TRANSFORMATION; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GENOTYPE; HISTOPATHOLOGY; HUMAN; NONHUMAN; ONCOCYTOMA; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; REVIEW; THYROID CARCINOMA; THYROID HURTHLE CELL TUMOR; THYROID PARAFOLLICULAR CELL; THYROID TUMOR; APOPTOSIS; BIOLOGICAL MODEL; CYTOLOGY; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; MITOCHONDRIAL GENE; PATHOLOGY; PHYSIOLOGY;

APOPTOSIS; CELL BIOLOGY; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; DNA, MITOCHONDRIAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MITOCHONDRIAL; HUMANS; MICRORNAS; MODELS, BIOLOGICAL; THYROID NEOPLASMS;

EID: 84864417959     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0354     Document Type: Review

References (119)

1. Abu-Amero KK, Alzahrani AS, Zou M & Shi Y 2005 High frequency of somatic mitochondrial DNA mutations in human thyroid carcinomas and complex I respiratory defect in thyroid cancer cell lines. Oncogene 24 1455-1460. (doi:10.1038/sj.onc.1208292)
2. Albores-Saavedra J 2010 Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of 8 cases. American Journal of Surgical Pathology 34 913. (doi:10.1097/PAS.0b013e3181d85d80)
3. Aldred MA, Ginn-Pease ME, Morrison CD, Popkie AP, Gimm O, Hoang-Vu C, Krause U, Dralle H, Jhiang SM, Plass C et al. 2003a Caveolin-1 and caveolin-2, together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis. Cancer Research 63 2864-2871.
4. Aldred MA, Morrison C, Gimm O, Hoang-Vu C, Krause U, Dralle H, Jhiang S & Eng C 2003b Peroxisome proliferator-activated receptor gamma is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas. Oncogene 22 3412-3416. (doi:10.1038/sj.onc.1206400)
5. Allia E, Cassoni P, Marrocco T, Volante M, Bussolati B, Wong M, Clark OH & Papotti M 2003 Oxyphilic and non-oxyphilic thyroid carcinoma cell lines differ in expressing apoptosis-related genes. Journal of Endocrinological Investigation 26 660-667.
6. Angell JE, Lindner DJ, Shapiro PS, Hofmann ER & Kalvakolanu DV 2000 Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach. Journal of Biological Chemistry 275 33416-33426. (doi:10.1074/jbc.M003929200)
7. Asioli S, Erickson LA, Sebo TJ, Zhang J, Jin L, Thompson GB & Lloyd RV 2010 Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases. American Journal of Surgical Pathology 34 44-52. (doi:10.1097/PAS. 0b013e3181c46677)
8. Attardi G, Yoneda M & Chomyn A 1995 Complementation and segregation behavior of disease-causing mitochondrial DNA mutations in cellular model systems. Biochimica et Biophysica Acta 1271 241-248. (doi:10.1016/0925-4439(95) 00034-2)
9. Baris O, Mirebeau-Prunier D, Savagner F, Rodien P, Ballester B, Loriod B, Granjeaud S, Guyetant S, Franc B, Houlgatte R et al. 2005 Gene profiling reveals specific oncogenic mechanisms and signaling pathways in oncocytic and papillary thyroid carcinoma. Oncogene 24 4155-4161. (doi:10.1038/sj.onc.1208578)
10. Bignell GR, Canzian F, Shayeghi M, Stark M, Shugart YY, Biggs P, Mangion J, Hamoudi R, Rosenblatt J, Buu P et al. 1997 Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. American Journal of Human Genetics 61 1123-1130. (doi:10.1086/301610)
11. Bonora E, Evangelisti C, Bonichon F, Tallini G & Romeo G 2006a Novel germline variants identified in the inner mitochondrial membrane transporter TIMM44 and their role in predisposition to oncocytic thyroid carcinomas. British Journal of Cancer 95 1529-1536. (doi:10.1038/sj.bjc.6603455)
12. Bonora E, Porcelli AM, Gasparre G, Biondi A, Ghelli A, Carelli V, Baracca A, Tallini G, Martinuzzi A, Lenaz G et al. 2006b Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Research 66 6087-6096. (doi:10.1158/0008-5472.CAN-06-0171)
13. Borutaite V & Brown GC 2003 Mitochondria in apoptosis of ischemic heart. FEBS Letters 541 1-5. (doi:10.1016/S0014-5793(03)00278-3)
14. Brandon M, Baldi P & Wallace DC 2006 Mitochondrial mutations in cancer. Oncogene 25 4647-4662. (doi:10.1038/sj.onc.1209607)
15. Bristow RG & Hill RP 2008 Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nature Reviews. Cancer 8 180-192. (doi:10.1038/ nrc2344)
16. Cameselle-Teijeiro J, Ferreira R, Caramés N, Abdulkader I, Máximo V, Soares P & Sobrinho-Simões M 2012 Absence of both the BRAF and the GRIM-19 mutations in oncocytic (Hürthle cell) solid cell nests of the thyrois. American Journal of Clinical Pathology 137 612-618. (doi:10.1309/AJCPB0RXYPACLL5K)
17. Canzian F, Amati P, Harach HR, Kraimps JL, Lesueur F, Barbier J, Levillain P, Romeo G & Bonneau D 1998 A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. American Journal of Human Genetics 63 1743-1748. (doi:10.1086/302164)
18. Cavaco BM, Batista PF, Sobrinho LG & Leite V 2008 Mapping a new familial thyroid epithelial neoplasia susceptibility locus to chromosome 8p23.1-p22 by high-density single-nucleotide polymorphism genome-wide linkage analysis. Journal of Clinical Endocrinology and Metabolism 93 4426-4430. (doi:10.1210/jc.2008-0449)
19. Chan DC 2006 Mitochondria: dynamic organelles in disease, aging, and development. Cell 125 1241-1252. (doi:10.1016/j.cell.2006.06.010)
20. Chandra D & Singh KK 2011 Genetic insights into OXPHOS defect and its role in cancer. Biochimica et Biophysica Acta 1807 620-625. (doi:10.1016/j.bbabio.2010.10.023)
21. Chen H & Chan DC 2010 Physiological functions of mitochondrial fusion. Annals of the New York Academy of Sciences 1201 21-25. (doi:10.1111/j.1749-6632.2010.05615.x)
22. Cheung CC, Carydis B, Ezzat S, Bedard YC & Asa SL 2001 Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. Journal of Clinical Endocrinology and Metabolism 86 2187-2190. (doi:10.1210/jc.86.5.2187)
23. Couto JP, Prazeres H, Castro P, Lima J, Máximo V, Soares P & Sobrinho-Simões M 2009 How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer. Journal of Clinical Pathology 62 414-421. (doi:10.1136/jcp.2008.055343)
24. Czarnecka AM, Kukwa W, Krawczyk T, Scinska A, Kukwa A & Cappello F 2010 Mitochondrial DNA mutations in cancer-from bench to bedside. Frontiers in Bioscience 15 437-460. (doi:10.2741/3629)
25. DeLellis RA LR, Heitz PU & Eng C Eds 2004 World health organization classification of tumours. In Pathology and Genetics of Tumours of Endocrine Glands. Lyon: IARC Press.
26. De Vries MM, Celestino R, Castro P, Eloy C, Máximo V, van der Wal JE, Plukker JTM, Links TP, Hofstra RMW, Sobrinho-Simões M & Soares P 2012 RET/PTC rearrangement is prevalent in follicular Hürthle cell carcinomas. Histopathology [in press]. (doi:10.1111/j.1365-2559.2012.04276.x)
27. Dominguez-Malagon H, Delgado-Chavez R, Torres-Najera M, Gould E & Albores-Saavedra J 1989 Oxyphil and squamous variants of medullary thyroid carcinoma. Cancer 63 1183-1188. (doi:10.1002/1097-0142(19890315)63:6〈1183:: AID-CNCR2820630624〉3.0.CO;2-3)
28. Evans HL & Vassilopoulou-Sellin R 1998 Follicular and Hurthle cell carcinomas of the thyroid: a comparative study. American Journal of Surgical Pathology 22 1512-1520. (doi:10.1097/00000478-199812000-00008)
29. Eze OP, Starker LF & Carling T 2011 The role of epigenetic alterations in papillary thyroid carcinogenesis. Journal of Thyroid Research 2011 895470. (doi:10.4061/2011/895470)
30. Firminger HI & Skelton FR 1953 Carcinoma of the thyroid: papillary adenocarcinoma occuring in twins and a case of Hürthle cell carcinoma; tumor conference. Journal of the Kansas Medical Society 54 427-432.
31. Fridman E, Dotan Z, Barshack I, David MB, Dov A, Tabak S, Zion O, Benjamin S, Benjamin H, Kuker H et al. 2010 Accurate molecular classification of renal tumors using microRNA expression. Journal of Molecular Diagnostics 12 687-696. (doi:10.2353/jmoldx.2010.090187)
32. Galusca B, Dumollard JM, Lassandre S, Niveleau A, Prades JM, Estour B & Peoc'h M 2005 Global DNA methylation evaluation: potential complementary marker in differential diagnosis of thyroid neoplasia. Virchows Archiv: an International Journal of Pathology 447 18-23. (doi:10.1007/s00428-005-1268-5)
33. Garcia-Rostan G & Sobrinho-Simões M 2011 Poorly differentiated thyroid carcinoma: an evolving entity. Diagnostic Histopathology 17 114-123. (doi:10.1016/j.mpdhp.2010.12.001)
34. Gasparre G, Porcelli AM, Bonora E, Pennisi LF, Toller M, Iommarini L, Ghelli A, Moretti M, Betts CM, Martinelli GN et al. 2007 Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. PNAS 104 9001-9006. (doi:10.1073/pnas.0703056104)
35. Gasparre G, Hervouet E, de Laplanche E, Demont J, Pennisi LF, Colombel M, Mege-Lechevallier F, Scoazec JY, Bonora E, meets R et al. 2008 Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma. Human Molecular Genetics 17 986-995. (doi:10.1093/hmg/ddm371)
36. Gasparre G, Kurelac I, Capristo M, Iommarini L, Ghelli A, Ceccarelli C, Nicoletti G, Nanni P, De Giovanni C, Scotlandi K et al. 2011 A mutation threshold distinguishes the antitumorigenic effects of the mitochondrial gene MTND1, an oncojanus function. Cancer Research 71 6220-6229. (doi:10.1158/0008- 5472.CAN-11-1042)
37. Graff JR, Greenberg VE, Herman JG, Westra WH, Boghaert ER, Ain KB, Saji M, Zeiger MA, Zimmer SG & Baylin SB 1998 Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma. Cancer Research 58 2063-2066.
38. Greco A, Borrello MG, Miranda C, Degl'Innocenti D & Pierotti MA 2009 Molecular pathology of differentiated thyroid cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging 53 440-453.
39. He H, Nagy R, Liyanarachchi S, Jiao H, Li W, Suster S, Kere J & de la Chapelle A 2009 A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24. Cancer Research 69 625-631. (doi:10.1158/0008-5472.CAN-08-1071)
40. Heddi A, Faure-Vigny H, Wallace DC & Stepien G 1996 Coordinate expression of nuclear and mitochondrial genes involved in energy production in carcinoma and oncocytoma. Biochimica et Biophysica Acta 1316 203-209. (doi:10.1016/0925-4439(96)00026-9)
41. Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B, Saito Y, Johnson RS, Kretzler M, Cohen CD et al. 2007 Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. Journal of Clinical Investigation 117 3810-3820. (doi:10.1172/JCI30487)
42. Hoos A, Stojadinovic A, Singh B, Dudas ME, Leung DH, Shaha AR, Shah JP, Brennan MF, Cordon-Cardo C & Ghossein R 2002 Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed via tissue microarrays. American Journal of Pathology 160 175-183. (doi:10.1016/S0002-9440(10)64361-1)
43. Huang S 1999 The retinoblastoma protein-interacting zinc finger gene RIZ in 1p36-linked cancers. Frontiers in Bioscience 4 D528-D532.
44. Huang SM, Lee JC, Wu TJ & Chow NH 2001 Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World Journal of Surgery 25 302-306. (doi:10.1007/s002680020085)
45. Huang G, Lu H, Hao A, Ng DC, Ponniah S, Guo K, Lufei C, Zeng Q & Cao X 2004 GRIM-19, a cell death regulatory protein, is essential for assembly and function of mitochondrial complex I. Molecular and Cellular Biology 24 8447-8456. (doi:10.1128/MCB.24.19.8447-8456.2004)
46. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H, Nakada K, Honma Y & Hayashi J 2008 ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 320 661-664. (doi:10.1126/science.1156906)
47. Jacques C, Baris O, Prunier-Mirebeau D, Savagner F, Rodien P, Rohmer V, Franc B, Guyetant S, Malthiery Y & Reynier P 2005 Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors. Journal of Clinical Endocrinology and Metabolism 90 2314-2320. (doi:10.1210/jc.2004-1337)
48. Jacques C, Fontaine JF, Franc B, Mirebeau-Prunier D, Triau S, Savagner F & Malthiery Y 2009 Death-associated protein 3 is overexpressed in human thyroid oncocytic tumours. British Journal of Cancer 101 132-138. (doi:10.1038/sj.bjc.6605111)
49. Katoh R, Harach HR & Williams ED 1998 Solitary, multiple, and familial oxyphil tumours of the thyroid gland. Journal of Pathology 186 292-299. (doi:10.1002/(SICI)1096-9896(1998110)186:3〈292::AID-PATH190〉3.0.CO;2- Y)
50. Kepes JJ 1983 Oncocytic transformation of choroid plexus epithelium. Acta Neuropathologica 62 145-148. (doi:10.1007/BF00684932)
51. Kitano M, Rahbari R, Patterson EE, Xiong Y, Prasad NB, Wang Y, Zeiger MA & Kebebew E 2011 Expression profiling of difficult-to-diagnose thyroid histologic subtypes shows distinct expression profiles and identify candidate diagnostic microRNAs. Annals of Surgical Oncology 18 3443-3452. (doi:10.1245/s10434-011-1766-4)
52. Lal G, Padmanabha L, Smith BJ, Nicholson RM, Howe JR, O'Dorisio MS & Domann FE Jr 2006 RIZ1 is epigenetically inactivated by promoter hypermethylation in thyroid carcinoma. Cancer 107 2752-2759. (doi:10.1002/cncr.22325)
53. LiVolsi VA, Albores-Saavedra J, Asa SL, Baloch ZW, Sobrinho-Simões M, Wenig B, DeLellis RA, Cady B, Mazzaferri EL, Hay I et al. 2004 Papillary carcinoma. In World Health Organization Classification of Tumours. Pathology and genetics of tumours of endocrine organs. Eds RA deLellis, RV Lloyd, PU Heitz & C Eng. Lyon: IARC Press.
54. Lu J, Sharma LK & Bai Y 2009 Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis. Cell Research 19 802-815. (doi:10.1038/cr.2009.69)
55. Malchoff CD, Sarfarazi M, Tendler B, Forouhar F, Whalen G, Joshi V, Arnold A & Malchoff DM 2000 Papillary thyroid carcinoma associatedwith papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. Journal of Clinical Endocrinology and Metabolism 85 1758-1764. (doi:10.1210/jc.85.5.1758)
56. Máximo V & Sobrinho-Simões M 2000a Hürthle cell tumours of the thyroid. A review with emphasis on mitochondrial abnormalities with clinical relevance. Virchows Archiv: an International Journal of Pathology 437 107-115. (doi:10.1007/s004280000219)
57. Máximo V & Sobrinho-Simões M 2000b Mitochondrial DNA 'common' deletion in Hürthle cell lesions of the thyroid. Journal of Pathology 192 561-562. (doi:10.1002/1096-9896(200012)192:4〈561::AID- PATH790〉3.0.CO;2-3)
58. Máximo V, Soares P, Rocha AS & Sobrinho-Simões M 1998 The common deletion of mitochondrial DNA is found in goiters and thyroid tumors with and without oxyphil cell change. Ultrastructural Pathology 22 271-273. (doi:10.3109/01913129809033479)
59. Máximo V, Soares P, Lima J, Cameselle-Teijeiro J & Sobrinho-Simões M 2002 Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hürthle cell tumors. American Journal of Pathology 160 1857-1865. (doi:10.1016/S0002-9440(10)61132-7)
60. Máximo V, Preto A, Crespo A, Rocha AS, Machado JC, Soares P & Sobrinho-Simões M 2004 Core I gene is overexpressed in Hürthle and non-Hürthle cell microfollicular adenomas and follicular carcinomas of the thyroid. BMC Cancer 4 12. (doi:10.1186/1471-2407-4-12)
61. Máximo V, Botelho T, Capela J, Soares P, Lima J, Taveira A, Amaro T, Barbosa AP, Preto A, Harach HR et al. 2005a Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hürthle cell) tumours of the thyroid. British Journal of Cancer 92 1892-1898. (doi:10.1038/sj.bjc.6602547)
62. Máximo V, Lima J, Soares P, Botelho T, Gomes L & Sobrinho-Simões M 2005b Mitochondrial D-Loop instability in thyroid tumours is not a marker of malignancy. Mitochondrion 5 333-340. (doi:10.1016/j.mito.2005.06.003)
63. Máximo V, Lima J, Soares P, Silva A, Bento I & Sobrinho-Simões M 2008 GRIM-19 in health and disease. Advances in Anatomic Pathology 15 46-53. (doi:10.1097/PAP.0b013e31815e5258)
64. Máximo V, Lima J, Soares P & Sobrinho-Simões M 2009 Mitochondria and cancer. Virchows Archiv: an International Journal of Pathology 454 481-495. (doi:10.1007/s00428-009-0766-2)
65. McKay JD, Lesueur F, Jonard L, Pastore A, Williamson J, Hoffman L, Burgess J, Duffield A, Papotti M, Stark M et al. 2001 Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. American Journal of Human Genetics 69 440-446. (doi:10.1086/321979)
66. McKay JD, Thompson D, Lesueur F, Stankov K, Pastore A, Watfah C, Strolz S, Riccabona G, Moncayo R, Romeo G et al. 2004 Evidence for interaction between the TCO and NMTC1 loci in familial non-medullary thyroid cancer. Journal of Medical Genetics 41 407-412. (doi:10.1136/jmg.2003.017350)
67. Meeusen S, McCaffery JM & Nunnari J 2004 Mitochondrial fusion intermediates revealed in vitro. Science 305 1747-1752. (doi:10.1126/science. 1100612)
68. Moreira S, Correia M, Soares P & Máximo V 2011 GRIM-19 function in cancer development. Mitochondrion 11 693-699. (doi:10.1016/j.mito. 2011.05.011)
69. Muller-Hocker J 1999 Immunoreactivity of p53, Ki-67, and Bcl-2 in oncocytic adenomas and carcinomas of the thyroid gland. Human Pathology 30 926-933. (doi:10.1016/S0046-8177(99)90246-0)
70. Nagamachi Y, Nakamura T & Yamada T 1973 Hurthle cell adenoma of the thyroid in identical twins with 13 years follow-up. Japanese Journal of Surgery 3 212-217. (doi:10.1007/BF02468775)
71. Nakada K, Inoue K, Ono T, Isobe K, Ogura A, Goto YI, Nonaka I & Hayashi JI 2001 Inter-mitochondrial complementation: mitochondria-specific system preventing mice from expression of disease phenotypes by mutant mtDNA. Nature Medicine 7 934-940. (doi:10.1038/90976)
72. Nesland JM, Sobrinho-Simões MA, Holm R, Sambade MC & Johannessen JV 1985 Hürthle-cell lesions of the thyroid: a combined study using transmission electron microscopy, scanning electron microscopy, and immunocytochemistry. Ultrastructural Pathology 8 269-290. (doi:10.3109/ 01913128509141518)
73. Nikiforova MN, Tseng GC, Steward D, Diorio D & Nikiforov YE 2008 MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. Journal of Clinical Endocrinology and Metabolism 93 1600-1608. (doi:10.1210/jc.2007-2696)
74. Ohama E & Ikuta F 1987 Involvement of choroid plexus in mitochondrial encephalomyopathy (MELAS). Acta Neuropathologica 75 1-7. (doi:10.1007/ BF00686785)
75. Pallante P, Visone R, Croce CM & Fusco A 2010 Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas. Endocrine-Related Cancer 17 F91-F104. (doi:10.1677/ERC-09-0217)
76. Pereira L, Soares P, Máximo V & Samuels DC 2012 Somatic mitochondrial DNA mutations in cancer escape purifying selection and high pathogenicity mutations lead to the oncocytic phenotype: pathogenicity analysis of reported somatic mtDNA mutations in tumors. BMC Cancer 12 53. (doi:10.1186/1471-2407-12-53)
77. Petros JA, Baumann AK, Ruiz-Pesini E, Amin MB, Sun CQ, Hall J, Lim S, Issa MM, Flanders WD, Hosseini SH et al. 2005 mtDNA mutations increase tumorigenicity in prostate cancer. PNAS 102 719-724. (doi:10.1073/pnas. 0408894102)
78. Piana S, Frasoldati A, Di Felice E, Gardini G, Tallini G & Rosai J 2010 Encapsulated well-differentiated follicular-patterned thyroid carcinomas do not play a significant role in the fatality rates from thyroid carcinoma. American Journal of Surgical Pathology 34 1560. (doi:10.1097/PAS. 0b013e3181efefed)
79. Polyak K, Li Y,ZhuH,LengauerC,Willson JK,MarkowitzSD, Trush MA, Kinzler KW& Vogelstein B 1998 Somatic mutations of the mitochondrial genome in human colorectal tumours. Nature Genetics 20 291-293. (doi:10.1038/3108)
80. Porcelli AM, Ghelli A, Ceccarelli C, Lang M, Cenacchi G, Capristo M, Pennisi LF, Morra I, Ciccarelli E, Melcarne A et al. 2010 The genetic and metabolic signature of oncocytic transformation implicates HIF1alpha destabilization. Human Molecular Genetics 19 1019-1032. (doi:10.1093/hmg/ddp566)
81. Pouyssegur J, Dayan F & Mazure NM 2006 Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441 437-443. (doi:10.1038/nature04871)
82. Pradella LM, Zuntini R, Magini P, Ceccarelli C, Neri I, Cerasoli S, Graziano C, Gasparre G & Turchetti D 2011 Two distinct thyroid tumours in a patient with Cowden syndrome carrying both a 10q23 and a mitochondrial DNA germline deletion. Journal of Medical Genetics 48 779-782. (doi:10.1136/ jmedgenet-2011-100152)
83. Prasad ML, Pellegata NS, Kloos RT, Barbacioru C, Huang Y & de la Chapelle A 2004 CITED1 protein expression suggests papillary thyroid carcinoma in high throughput tissue microarray-based study. Thyroid 14 169-175. (doi:10.1089/105072504773297830)
84. Prazeres H, Rodrigues F, Soares P, Naidenov P, Figueiredo P, Campos B, Lacerda M & Martins T 2008 Loss of heterozygosity at 19p13.2 and 2q21 in tumours from familial clusters of non-medullary thyroid carcinoma. Familial Cancer 7 141-149. (doi:10.1007/s10689-007-9160-x)
85. Prazeres H, Torres J, Soares P & Sobrinho-Simões M 2010 The familial counterparts of follicular cell-derived thyroid tumors. International Journal of Surgical Pathology 18 233-242. (doi:10.1177/1066896910366442)
86. Rehling P, Brandner K & Pfanner N 2004 Mitochondrial import and the twin-pore translocase. Nature Reviews. Molecular Cell Biology 5 519-530. (doi:10.1038/nrm1426)
87. Rocha AS, Soares P, Seruca R, Máximo V, Matias-Guiu X, Cameselle-Teijeiro J & Sobrinho-Simões M 2001 Abnormalities of the E-cadherin/catenin adhesion complex in classical papillary thyroid carcinoma and in its diffuse sclerosing variant. Journal of Pathology 194 358-366.
88. Rosai J, Carcangiu ML & DeLellis RA 1992 Tumours of the thyroid gland. In Atlas of Tumor Pathology, Fascicle 5, Series 3. Ed J Rosai. Washington, DC, USA: Armed Force Institute of Pathology.
89. Savagner F, Mirebeau D, Jacques C, Guyetant S, Morgan C, Franc B, Reynier P & Malthiery Y 2003 PGC-1-related coactivator and targets are upregulated in thyroid oncocytoma. Biochemical and Biophysical Research Communications 310 779-784. (doi:10.1016/j.bbrc.2003.09.076)
90. Shidara Y, Yamagata K, Kanamori T, Nakano K, Kwong JQ, Manfredi G, Oda H & Ohta S 2005 Positive contribution of pathogenic mutations in the mitochondrial genome to the promotion of cancer by prevention from apoptosis. Cancer Research 65 1655-1663. (doi:10.1158/0008-5472.CAN-04-2012)
91. Silver MM, Burns JE, Sethi RK & Rowe RD 1980 Oncocytic cardiomyopathy in an infant with oncocytosis in exocrine and endocrine glands. Human Pathology 11 598-605. (doi:10.1016/S0046-8177(80)80071-2)
92. Sobrinho-Simões MA, Nesland JM, Holm R, Sambade MC & Johannessen JV 1985 Hürthle cell and mitochondrion-rich papillary carcinomas of the thyroid gland: an ultrastructural and immunocytochemical study. Ultrastructural Pathology 8 131-142. (doi:10.3109/01913128509142147)
93. Sobrinho-Simões M, Asa SL, Kroll TG, Nikiforov YE, DeLellis RA, Farid P, Kitamura Y, Noguchi S, Eng C, Harach HR et al. 2004 Follicular carcinoma. In World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Eds RA deLellis, RV Lloyd, PU Heitz & C Eng. Lyon: IARC Press.
94. Sobrinho-Simões M, Máximo V, Castro IV, Fonseca E, Soares P, Garcia-Rostan G & Oliveira MC 2005 Hürthle (oncocytic) cell tumors of thyroid: etiopathogenesis, diagnosis and clinical significance. International Journal of Surgical Pathology 13 29-35. (doi:10.1177/106689690501300104)
95. Sobrinho-Simões M, Eloy C, Magalhaes J, Lobo C & Amaro T 2011 Follicular thyroid carcinoma. Modern Pathology 24 (Suppl 2) S10-S18. (doi:10.1038/modpathol.2010.133)
96. Stankov K, Pastore A, Toschi L, McKay J, Lesueur F, Kraimps J, Bonneau D, Gibelin H, Levillain P, Volante M et al. 2004 Allelic loss on chromosomes 2q21 and 19p 13.2 in oxyphilic thyroid tumors. International Journal of Cancer 111 463-467. (doi:10.1002/ijc.20259)
97. Suh I, Filetti S, Vriens MR, Guerrero MA, Tumino S, Wong M, Shen WT, Kebebew E, Duh QY & Clark OH 2009 Distinct loci on chromosome 1q21 and 6q22 predispose to familial nonmedullary thyroid cancer: a SNP array-based linkage analysis of 38 families. Surgery 146 1073-1080. (doi:10.1016/j.surg.2009.09.012)
98. Takai D, Isobe K & Hayashi J 1999 Transcomplementation between different types of respiration-deficient mitochondria with different pathogenic mutant mitochondrial DNAs. Journal of Biological Chemistry 274 11199-11202. (doi:10.1074/jbc.274.16.11199)
99. Tanji K, Schon EA, DiMauro S & Bonilla E 2000 Kearns-Sayre syndrome: oncocytic transformation of choroid plexus epithelium. Journal of Neurological Sciences 178 29-36. (doi:10.1016/S0022-510X(00)00354-3)
100. Trovisco V, Vieira de Castro I, Soares P, Máximo V, Silva P, Magalhaes J, Abrosimov A, Guiu XM & Sobrinho-Simões M 2004 BRAF mutations are associated with some histological types of papillary thyroid carcinoma. Journal of Pathology 202 247-251. (doi:10.1002/path.1511)
101. Venkataraman GM, Yatin M, Marcinek R & Ain KB 1999 Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I - symporter gene methylation status. Journal of Clinical Endocrinology and Metabolism 84 2449-2457. (doi:10.1210/jc.84.7.2449)
102. Volante M, Papotti M, Gugliotta P, Migheli A & Bussolati G 2001 Extensive DNA fragmentation in oxyphilic cell lesions of the thyroid. Journal of Histochemistry and Cytochemistry 49 1003-1011. (doi:10.1177/002215540104900808)
103. Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, Lloyd RV, LiVolsi VA, Papotti M, Sobrinho-Simões M et al. 2007 Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. American Journal of Surgical Pathology 31 1256-1264. (doi:10.1097/PAS.0b013e3180309e6a)
104. Wallace DC 1986 Mitochondrial genes and disease. Hospital Practice 21 77-87.
105. Wallace DC 1999 Mitochondrial diseases in man and mouse. Science 283 1482-1488. (doi:10.1126/science.283.5407.1482)
106. Wang D, Feng JF, Zeng P, Yang YH, Luo J & Yang YW 2011 Total oxidant/antioxidant status in sera of patients with thyroid cancers. Endocrine-Related Cancer 18 773-782. (doi:10.1530/ERC-11-0230)
107. Warburg O 1956a On respiratory impairment in cancer cells. Science 124 269-270.
108. Warburg O 1956b On the origin of cancer cells. Science 123 309-314. (doi:10.1126/science.123.3191.309)
109. Weber F, Aldred MA, Morrison CD, Plass C, Frilling A, Broelsch CE, Waite KA & Eng C 2005 Silencing of the maternally imprinted tumor suppressor ARHI contributes to follicular thyroid carcinogenesis. Journal of Clinical Endocrinology and Metabolism 90 1149-1155. (doi:10.1210/jc.2004-1447)
110. Widder S, Guggisberg K, Khalil M & Pasieka JL 2008 A pathologic re-review of follicular thyroid neoplasms: the impact of changing the threshold for the diagnosis of the follicular variant of papillary thyroid carcinoma. Surgery 144 80-85. (doi:10.1016/j.surg.2007.11.014)
111. Wilson C 2010 Cancer: microRNA expression provides clues about the aggressiveness of papillary thyroid carcinoma. Nature Reviews. Endocrinology 6 416. (doi:10.1038/nrendo.2010.97)
112. Woodford RL, Nikiforov YE, Hunt JL, Bellizzi AM, Zhang X, Mills SE & Stelow EB 2010 Encapsulated papillary oncocytic neoplasms of the thyroid: morphologic, immunohistochemical, and molecular analysis of 18 cases. American Journal of Surgical Pathology 34 1582-1590. (doi:10.1097/PAS.0b013e3181f2d820)
113. Xing M 2007 Gene methylation in thyroid tumorigenesis. Endocrinology 148 948-953. (doi:10.1210/en.2006-0927)
114. Xing M 2012 Oxidative stress: a new risk factor for thyroid cancer. Endocrine-Related Cancer 19 C7-C11. (doi:10.1530/ERC-11-0360)
115. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC & Wu KJ 2008 Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nature Cell Biology 10 295-305. (doi:10.1038/ncb1691)
116. Yeh JJ, Lunetta KL, Van Orsouw NJ, Moore FD Jr, Mutter GL, Vijg J, Dahia PL & Eng C 2000 Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours. Oncogene 19 2060-2066. (doi:10.1038/sj.onc.1203537)
117. Yoneda M, Chomyn A, Martinuzzi A, Hurko O & Attardi G 1992 Marked replicative advantage of human mtDNA carrying a point mutation that causes the MELAS encephalomyopathy. PNAS 89 11164-11168. (doi:10.1073/pnas.89.23.11164)
118. Zimmermann FA, Mayr JA, Neureiter D, Feichtinger R, Alinger B, Jones ND, Eder W, Sperl W & Kofler B 2009 Lack of complex I is associated with oncocytic thyroid tumours. British Journal of Cancer 100 1434-1437. (doi:10.1038/sj.bjc.6605028)
119. Zimmermann FA, Mayr JA, Feichtinger R, Neureiter D, Lechner R, Koegler C, Ratschek M, Rusmir H, Sargsyan K, Sperl W et al. 2011 Respiratory chain complex I is a mitochondrial tumor suppressor of oncocytic tumors. Frontiers in Bioscience 3 315-325.